Clinical Trial Update: Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of anti-CD19 CAR-T cells with an inducible caspase-9 safety switch for B-cell lymphoma, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Immune System Diseases
• Immunoproliferative Disorders
• Lymphatic Diseases
• Lymphoma

Drugs mentioned

• Anti-CD19 CAR-T cells with inducible caspase-9 safety switch (CAR-T cell therapy with iCasp9 safety switch)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Lymphoma, Lymphoma, B-Cell | Phase 1 | Status: ACTIVE_NOT_RECRUITING